Nicox S.A. (LON:0RCQ)

Market Cap	27.97M +62.6%
Revenue (ttm)	2.84M -63.4%
Net Income	-23.20M
EPS	-0.32
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,959
Average Volume	19,347
Open	0.3760
Previous Close	0.3750
Day's Range	0.3760 - 0.3870
52-Week Range	0.2000 - 0.6500
Beta	0.29
RSI	60.74
Earnings Date	Jan 23, 2026

About Nicox

Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve eye health. The company’s lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. It also develops NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b cli...

• Industry: Pharmaceutical Preparations
• Founded: 1996
• Employees: 5
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RCQ

Financial Performance

In 2024, Nicox's revenue was 7.86 million, an increase of 13.84% compared to the previous year's 6.90 million. Losses were -22.39 million, 7.23% more than in 2023.

Financial numbers in EUR